TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12391107

Group type: EXPERIMENTAL
Intervention: Hypoxic training (Fi(O(2)) = 15.3%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normoxic training (Fi(O(2)) = 20.9%)
Number of subjects: 16
Study: 11022056

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 29
Study: 8623181

Group type: EXPERIMENTAL
Intervention: MMF 3 g
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: MMF 2 g
Number of subjects: 503

Group type: COMPARATOR
Intervention: AZA
Number of subjects: 503
Study: 8445015

Group type: EXPERIMENTAL
Intervention: Estradiol (0.2 mg/day percutaneously)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no estradiol treatment)
Number of subjects: 9
Study: 3518730

Group type: EXPERIMENTAL
Intervention: 1.5 mg trimoprostil administered 30 min before meals
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.5 mg trimoprostil administered 30 min after meals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29227962

Group type: EXPERIMENTAL
Intervention: Video assisted structured aerobic exercise module (10 sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Video assisted structured aerobic exercise module
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 26432623

Group type: EXPERIMENTAL
Intervention: Basal-Bolus Insulin (B-BI)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sliding Scale Insulin (SSI)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups (B-BI and SSI)
Number of subjects: 64
Study: 24338466

Group type: EXPERIMENTAL
Intervention: Intrathecal 7.5 mg Levobupivacaine 0.25% plus sufentanil 2.5 μg (Group L0.25)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intrathecal 7.5 mg Levobupivacaine 0.50% plus sufentanil 2.5 μg (GroupControl)
Number of subjects: 70
Study: 21289522

Group type: EXPERIMENTAL
Intervention: AT-101 (40 mg b.i.d. × 3 days) plus docetaxel (75 mg/m on day 1) every 21 days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo plus docetaxel (75 mg/m on day 1) every 21 days
Number of subjects: 106
Study: 19649687

Group type: EXPERIMENTAL
Intervention: Morphine (MG)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oxycodone (OG)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 135
Study: 17372130

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Glatiramer acetate 20 mg
Number of subjects: 90
Study: 15035723

Group type: EXPERIMENTAL
Intervention: Sodium antimony gluconate (SAG) 20 mg/kg daily for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amphotericin B (AMB) 1 mg/kg daily for 20 days
Number of subjects: 60
Study: 11511481

Group type: EXPERIMENTAL
Intervention: Community hospital transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remaining in a district general hospital
Number of subjects: 0
Study: 9663178

Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8154037

Group type: EXPERIMENTAL
Intervention: DILT (60 mg b.i.d.)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: KETO (200 mg/day)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (TRIPLE with CsA 8 mg/kg/day)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: KETO
Number of subjects: 3
Study: 3292185

Group type: EXPERIMENTAL
Intervention: Amoxicillin (3 g as a single dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg as a single dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Erythromycin (1.5 g plus another 0.5 g after six hours)
Number of subjects: 12
Study: 30720697

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic splenectomy (HALS)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Complete laparoscopic splenectomy (LS)
Number of subjects: 91
Study: 28283600

Group type: EXPERIMENTAL
Intervention: Admission hyperglycemia (blood glucose ≥7.8 mmol/L)
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Admission hyperglycemia in patients with diabetes mellitus (n = 418)
Number of subjects: 1676
Study: 26585940

Group type: EXPERIMENTAL
Intervention: Mammalian cell-derived quadrivalent influenza vaccine (QIVc)
Number of subjects: 2333

Group type: COMPARATOR
Intervention: Trivalent influenza vaccines (TIV1c/TIV2c)
Number of subjects: 2333
Study: 24251363

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing of warfarin
Number of subjects: 455

Group type: COMPARATOR
Intervention: Standard dosing of warfarin (control)
Number of subjects: 455
Study: 21236548

Group type: EXPERIMENTAL
Intervention: Automated External Defibrillator (AED)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Vibration measurement on the floor of the helicopter
Number of subjects: 2
Study: 18545884

Group type: EXPERIMENTAL
Intervention: LigaSure haemorrhoidectomy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Diathermy haemorrhoidectomy
Number of subjects: 44
Study: 21334545

Group type: EXPERIMENTAL
Intervention: Augmented soft tissue mobilization (ASTM) twice a week for 5 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Advice on the natural evolution of lateral epicondylitis, computer ergonomics, and stretching exercises (Control)
Number of subjects: 27
Study: 16162880

Group type: EXPERIMENTAL
Intervention: Early invasive management
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Selectively invasive management
Number of subjects: 1200
Study: 11844507

Group type: EXPERIMENTAL
Intervention: Redesigned community postnatal care led by midwives
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Control group care (standard care)
Number of subjects: 2064
Study: 9828756

Group type: EXPERIMENTAL
Intervention: HF/SW snacks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LF/NSW snacks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HF snacks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LF snacks
Number of subjects: 36

Group type: COMPARATOR
Intervention: General snack consumption
Number of subjects: 36
Study: 8569932

Group type: EXPERIMENTAL
Intervention: Pyloriset IgG at a cut-off value of 500 U/l
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Pyloriset IgG at a cut-off value of 350 U/l (excluding patients aged above 70 years)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Pyloriset IgG in patients under the age of 45 years
Number of subjects: 154
Study: 2548135

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens + 5 mg medroxyprogesterone acetate
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 1.25 mg conjugated equine estrogens + 5 mg medroxyprogesterone acetate
Number of subjects: 95

Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine estrogens + placebo
Number of subjects: 95

Group type: COMPARATOR
Intervention: 1.25 mg conjugated equine estrogens + placebo
Number of subjects: 95
Study: 321823

Group type: EXPERIMENTAL
Intervention: Plasminogen
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 29879536

Group type: EXPERIMENTAL
Intervention: Extinction_CS+
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extinction_Singular
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extinction_Variety
Number of subjects: 0
Study: 27160404

Group type: EXPERIMENTAL
Intervention: Nitroglycerin‐mediated dilation (NMD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flow‐mediated dilation (FMD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other vascular function tests (VFTs)
Number of subjects: 0
Study: 25023444

Group type: EXPERIMENTAL
Intervention: High-ganglioside complex milk lipid (CML)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control
Number of subjects: 450
Study: 22642526

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 41
Study: 20689094

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 19

Group type: COMPARATOR
Intervention: Seated position
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 19
Study: 18182665

Group type: EXPERIMENTAL
Intervention: Docetaxel plus prednisone (D3P)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel plus prednisone (D1P)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Mitoxantrone plus prednisone (MP)
Number of subjects: 1006
Study: 15795146

Group type: EXPERIMENTAL
Intervention: PCEA plus continuous background infusion (4 mL/h plus an hourly maximum of three 4‐mL boluses on demand, lock‐out time 20 min)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Demand-only PCEA (hourly maximum of four 4‐mL boluses, lock‐out time 15 min)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both regimens (PCEA plus continuous background infusion and demand-only PCEA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PCEA plus continuous background infusion
Number of subjects: 66

Group type: COMPARATOR
Intervention: Demand-only PCEA
Number of subjects: 66
Study: 14500274

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound measurement of speed of sound (SOS) at the tibia using SoundScan 2000 device
Number of subjects: 1596

Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for osteoporosis based on SOS<or=3733 m s(‐1) and T‐score<or=‐3.8
Number of subjects: 1596

Group type: EXPERIMENTAL
Intervention: Diagnostic criteria based on SOS<or=3800 m s(‐1) and T‐score<or=‐2.0
Number of subjects: 1596

Group type: EXPERIMENTAL
Intervention: Comparison of SOS between pre-menopausal and post-menopausal women aged 40-59 years
Number of subjects: 1596

Group type: EXPERIMENTAL
Intervention: Prevalence of osteoporosis in pre-menopausal vs post-menopausal women aged 40-59 years
Number of subjects: 1596
Study: 10396715

Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9345495

Group type: EXPERIMENTAL
Intervention: Standardized and validated cross-lingual experimental task
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 77
Study: 1684465

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non‐anoic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (unexposed)
Number of subjects: 0
Study: 7006557

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Imipramine hydrochloride (pharmacotherapy)
Number of subjects: 44
Study: 31519673

Group type: EXPERIMENTAL
Intervention: Journeying through Dementia (JtD) intervention
Number of subjects: 486

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 486
Study: 28301098

Group type: EXPERIMENTAL
Intervention: 2 mg AER (under fasting conditions)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg AER (under fed conditions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2 mg CARP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg AER
Number of subjects: 30
Study: 26875003

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 56
Study: 25400472

Group type: EXPERIMENTAL
Intervention: Perioperative restricted fluid therapy (R, n = 96)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Perioperative standard fluid therapy (S, n = 89)
Number of subjects: 185
Study: 22572687

Group type: EXPERIMENTAL
Intervention: Early colonoscopy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Colonoscopy 6 weeks later
Number of subjects: 83
Study: 20482508

Group type: EXPERIMENTAL
Intervention: Buspirone (anxiolytic, 5-HT(1A) partial agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritanserin (serotonergic drug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron (5-HT(3) antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSRIs (Selective serotonin reuptake inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study: 18397680

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study: 16208053

Group type: EXPERIMENTAL
Intervention: Breath holding children
Number of subjects: 50
Study: 11879258

Group type: COMPARATOR
Intervention: Erythromycin (500 mg twice daily on days 2-6)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Azithromycin (500 mg once daily on days 2-4)
Number of subjects: 50
Study: 12489923

Group type: EXPERIMENTAL
Intervention: Resistance training (8-week program, 6 days/week)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Resistance training (T)
Number of subjects: 19
Study: 10689656

Group type: EXPERIMENTAL
Intervention: Initial motivationally based, four-session outpatient treatment; n = 67
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Supplemental intervention for nonresponders; n = 33
Number of subjects: 136

Group type: COMPARATOR
Intervention: Nonresponders without supplemental intervention; n = 36
Number of subjects: 136
Study: 7510276

Group type: EXPERIMENTAL
Intervention: Cisplatin-bleomycin-5-fluorouracil (PBF) in 31 patients
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cisplatin-5-fluorouracil (PF) in 33 patients
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cisplatin-5-fluorouracil (PF)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cisplatin-bleomycin-5-fluorouracil (PBF)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overall survival with laryngeal preservation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overall 2-year survival rates
Number of subjects: 64
Study: 2518847

Group type: EXPERIMENTAL
Intervention: Mesasal tablets, 2 x 250 mg, fasting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mesasal tablets, 2 x 250 mg, fed
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salazopyrin tablets, 3 x 500 mg (corresponding to 576 mg 5‐ASA), fasting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mesasal suppository, 1 x 500 mg, fasting
Number of subjects: 12
Study: 568493

Group type: EXPERIMENTAL
Intervention: 110 dB white noise stimulus
Number of subjects: 48

Group type: COMPARATOR
Intervention: 60 dB white noise stimulus
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fast-paced mental arithmetic task
Number of subjects: 48

Group type: COMPARATOR
Intervention: Slow-paced mental arithmetic task
Number of subjects: 48
Study: 31495292

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg once then 850 mg twice daily for two weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metformin (double dose 1700 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metformin (single dose 850 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metformin (both doses)
Number of subjects: 24
Study: 31229621

Group type: EXPERIMENTAL
Intervention: Phone health coaching to help select and enroll in WMPs
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (no health coaching)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Phone health coaching (≥4 calls)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Phone health coaching
Number of subjects: 168
Study: 28345778

Group type: EXPERIMENTAL
Intervention: Intravaginal pressure biofeedback (P‐BF) assisted pelvic floor muscle (PFM) exercises
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Perineal electromyographic biofeedback (EMG‐BF) assisted pelvic floor muscle (PFM) exercises
Number of subjects: 53

Group type: COMPARATOR
Intervention: PFM home exercise program alone
Number of subjects: 53
Study: 25261154

Group type: EXPERIMENTAL
Intervention: Feedback about performance on a 10-meter walk (speed only)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Walking speed feedback plus a review of walking activity recorded by the sensors (augmented)
Number of subjects: 135
Study: 23829147

Group type: EXPERIMENTAL
Intervention: Structured peer assessment based on Calibrated Peer Review
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no facilitative resources)
Number of subjects: 48
Study: 21291446

Group type: EXPERIMENTAL
Intervention: Mentoring (treatment group)
Number of subjects: 1139

Group type: COMPARATOR
Intervention: No mentoring (control group)
Number of subjects: 1139
Study: 19836995

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at varying intensities applied to the posterior fossa (PF) with ISIs of 5 or 7 ms
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at varying intensities applied to the posterior fossa (PF) with ISI of 3 ms
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PF stimuli alone
Number of subjects: 11
Study: 17082240

Group type: EXPERIMENTAL
Intervention: ACEi (trandolapril 2 mg/d)
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: ndCCB (verapamil SR 240 mg/d)
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Veratran (trandolapril 2 mg/d plus verapamil SR 180 mg/d)
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1204
Study: 15021839

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 24
Study: 11704899

Group type: EXPERIMENTAL
Intervention: Training of Emotional Intelligence (TEI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Integrated Psychological Therapy Program (IPT)
Number of subjects: 41
Study: 9265917

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 817

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 817
Study: 7924757

Group type: EXPERIMENTAL
Intervention: Indomethacin (repeated doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indomethacin (third dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indomethacin (all doses)
Number of subjects: 10
Study: 2891365

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neostigmine 5 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Spontaneous recovery (no intervention)
Number of subjects: 50
Study: 30081211

Group type: EXPERIMENTAL
Intervention: Cross-training in apnea and physical activity (CT; n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Apnea training only (AT; n = 10)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (CG; n = 9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cross-training in apnea and physical activity (CT)
Number of subjects: 29
Study: 29409488

Group type: EXPERIMENTAL
Intervention: 99mTechnetium‐labelled monodisperse salbutamol (1.5 μm)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 99mTechnetium‐labelled monodisperse salbutamol (6 μm)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polydisperse nebulisation of salbutamol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polydisperse pMDI inhalation of salbutamol (400 μg)
Number of subjects: 9
Study: 26712188

Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy with fiberoptic bronchoscopy (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Percutaneous dilatational tracheostomy without fiberoptic bronchoscopy (Group A)
Number of subjects: 60
Study: 24748400

Group type: EXPERIMENTAL
Intervention: Propofol-nitrous oxide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sevoflurane-nitrous oxide
Number of subjects: 100
Study: 22771137

Group type: EXPERIMENTAL
Intervention: Ezogabine/retigabine
Number of subjects: 336
Study: 20683947

Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) 23-28 mg/kg/day
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 17630563

Group type: EXPERIMENTAL
Intervention: Protease inhibitor-based antiretroviral therapy
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (general)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: HCV genotype 1 or 4 infection
Number of subjects: 379
Study: 15677384

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12697595

Group type: EXPERIMENTAL
Intervention: Ropivacaine 15 mg plus morphine 150 micro g (RM group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine 15 mg plus morphine 150 micro g (BM group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups (RM and BM)
Number of subjects: 50
Study: 10823363

Group type: EXPERIMENTAL
Intervention: Hypericum (LI 160) 600 mg/d for 1 week, then 900 mg/d for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sertraline 50 mg/d for 1 week, then 75 mg/d for 6 weeks
Number of subjects: 30
Study: 9032863

Group type: EXPERIMENTAL
Intervention: High dose Gamma Knife treatment (surface dose 58 +/- 9 Gy, maximum dose 81 +/- 15 Gy, mean dose 66 +/- 11 Gy) in Group A (10 patients, follow-up 24 +/- 4 months)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lower dose Gamma Knife treatment (surface dose 41 +/- 3 Gy, maximum dose 76 +/- 10 Gy, mean dose 53 +/- 11 Gy) in Group B (9 patients, follow-up 16 +/- 2 months)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lower dose Gamma Knife treatment (surface dose 42 +/- 3 Gy, maximum dose 72 +/- 16 Gy, mean dose 54 +/- 6 Gy) in Group C (17 patients, follow-up 6 +/- 3 months)
Number of subjects: 36
Study: 1523880

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine (11 micrograms of each oligosaccharide and 88 micrograms of CRM 197)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6389288

Group type: EXPERIMENTAL
Intervention: Quinine-papaverine combination (3 X 1 coated tablet per day for four weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Papaverine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2867260

Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46